Ankh Life Sciences Limited

Jacam Chemicals, LLC

Jacam Chemical Company 2013, LLC

Ions Pharmaceutical S.à R.l.

Jacam Chemical Partners, Ltd.

Jacam Chemical Company, Inc.

Other

Life Plus, LLC

Ces Technology S.a.r.l.

Jacam Chemical, LLC

Ces International Operations S.a R.l.

Ces Global Operations Ag

Gene H Zaid

Beth Ann Wolf

Thomas W Burgoyne

Cameron E West

Robert Preston Moore

Kim Brashear

Rachel Elizabeth Ropp

David Jay Rose

Krishna Mohan Donavalli

Harlan G McCormack

Larry D Crow

Jason H West

Rajni Verma

Thomas Joseph Fortune

Brian Scott Johnathan Blagg

James C Baker

David Horton

Nader M Obeid

Stephen Philip Rivas

Gene F Brock

Byron G Owen

Ivan Clark Barr

Gary W Zorn

Donald W Sanders

Vishal Chandrakumar Birar

David P Horton

Low-temperature syntheses of thymoquinone/harmaline compounds which are useful for the treatment of human diabetes and cancers, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

Low-temperature synthesis of thymoquinone and harmaline compounds

Human therapeutic compositions are provided, comprising compounds including a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compounds are the reaction products of aldehyde and harmaline components. The compositions exhibit anti-cancer properties, especially against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

Therapeutic agents and uses thereof

The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments.

Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Methods for treating plasma cell neoplasm with human therapeutic agents

Novel compounds which inhibit DYRK1A activity comprise thymoquinone derivatives including a pair of substituted or unsubstituted six-membered carbon rings selected from phenyl and cyclohexadiene linked by an alkyl or alkenyl linker. Each six-membered ring includes at least one oxygen-bearing substituent selected from carbonyl oxygens, hydroxyls, alkoxyls, and halogenated derivatives thereof. The compounds can be administered to mammalian subjects for inhibition of DYRK1A kinase proteins.

Inhibition of DYRK1A kinase

Methods for the synthesis of harmine comprise reacting harmaline with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in the presence of a diacid catalyst. In an embodiment, the synthesis is carried out using a reaction mixture of harmaline, DDQ, THF solvent, and succinic acid; the reaction is carried out under an inert atmosphere with refluxing for a period of 4-12 hours.

Harmine synthesis

The treatment of human subjects suffering from COVID-19 comprises the step of administering to the human subjects a medicament selected from the group consisting of 1,3-bis(7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)propane, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts thereof. The medicament may also be contacted with SARS-CoV-2 virus for inhibition of the virus.

Inhibition of COVID-19 virus

Topical medicaments for the treatment of mammalian skin are provided, which include an actives fraction and a carrier fraction; the actives fraction comprises individual amounts of turmeric,, and. In other embodiments, the actives fraction includes additional ingredients, including Vitamin C, &#x3b2;-sitosterol, and vanillin compound(s). The medicaments are useful in the treatment of a wide variety of conditions.

Topical medicaments

New compositions of matter useful for the treatment of human diabetes and cancers comprise the reaction products of thymoquinone and harmaline or harmaline-like compounds, such as &#x3b2;-carboline compounds, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

Thymoquinone/harmaline and related reaction products

Low-temperature syntheses of thymoquinone/harmaline compounds are provided which give increased yields of desirable products having molecular weights of from about 360-380. The syntheses involve carrying out reactions between thymoquinone and harmaline and a non-interfering solvent at a temperature of less than about 10&#xb0; C.

Methods for treating melanoma with human therapeutic agents

Mammalian nutritional supplements comprising individual quantities of turmeric,, andare provided, which promote several aspects of human health, and canine health. Advantageously, the turmeric is present in an amount greater than that ofor, and the supplements may contain additional beneficial ingredients, such as &#x3b2;-sitosterol, vanillin, garlic, and Vitamin C.

Nutritional supplement for mammals

Novel fused tricyclic or bicyclic dimers, such as &#x3b2;-carboline and quinoline moieties with a central linker, exhibit anti-cancer activities against a variety of human cancer cell lines. The dimer compounds can be used in anti-cancer therapeutic compositions useful in the treatment of human cancers.

Fused polycyclic dimers

Growing community of inventors

Sterling, KS, United States of America

Gene H Zaid